市場調查報告書
商品編碼
833128

美國的非腫瘤生物醫藥品市場 - 市場規模,佔有率,預測,市場機會分析 2018年∼2026年

U.S. Non-oncology Biopharmaceuticals Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

出版日期: | 出版商: Coherent Market Insights | 英文 224 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

生物醫藥品,是用生物製造或合成的高分子蛋白質及肽。生物醫藥品再分類為生物製藥和生物相似藥。

本報告提供美國的非腫瘤生物醫藥品市場調查,市場概要,各產品類型、醫藥品分類、適應疾病的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,償付方案,市場佔有率,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 假設
  • 簡稱

第2章 市場範圍

  • 報告的說明
  • 市場定義和範圍
  • 摘要整理
  • 市場片段:各產品類型
  • 市場片段:各醫藥品分類
  • 市場片段:各適應疾病
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,市場趨勢

  • 市場動態
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 最近產品認證/銷售
  • 合併、收購方案
  • 法規方案
  • 償付方案
  • PEST分析
  • 市場課題
  • 非腫瘤生技藥品前十名品牌的佔有率
  • 主要生物醫藥品的投藥方法
  • 管理方式分析
  • 流行病學
  • PEST分析
  • 波特的五力分析

第4章 美國的非腫瘤生物醫藥品市場:各產品類型

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場趨勢:各產品類型
  • 生物製藥
  • 生物相似藥

第5章 美國的非腫瘤生物醫藥品市場:各醫藥品分類

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場趨勢:各醫藥品分類
  • 血液因子
  • 肉毒桿菌
  • 細胞聚落刺激因子
  • 酵素補充療法
  • 促血紅細胞生長素
  • 融合蛋白質
  • 人體生長荷爾蒙
  • 干擾素
  • 單株抗體
  • 重組胰島素注射液
  • 疫苗
  • 其他

第6章 美國的非腫瘤生物醫藥品市場:各適應疾病

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場趨勢:各適應疾病
  • 老年性黃斑部病變
  • 貧血
  • 僵直性脊椎炎
  • 克隆氏症
  • 囊狀纖維化症
  • 糖尿病
  • 血友病
  • B型肝炎
  • 多發性硬化症
  • 骨質疏鬆症
  • 乾癬
  • 乾癬性關節炎
  • 慢性風濕病
  • 潰瘍性大腸炎
  • 其他

第7章 競爭環境

  • 熱圖分析
  • 企業簡介
    • Sanofi S.A.
    • Pfizer, Inc.
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Bristol - Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • Novo Nordisk A/S
    • GlaxoSmithKline plc.
    • UCB Pharma
    • Teva Pharmaceutical Industries Ltd.
    • 武田藥品工業
    • AstraZeneca Plc
    • Mylan N.V.
    • LEO Pharma A/S
    • Boehringer Ingelheim GmbH
    • Alexion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Elusys Therapeutics, Inc.
    • Swedish Orphan Biovitrum AB
    • Samsung Bioepis NL B.V.
    • Biogen Inc.
    • Theratechnologies Inc.

第8章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Biopharmaceuticals are complex, high molecular weight proteins and peptides that are produced or synthesized from living biological source. Biopharmaceuticals are further divided into biologics and biosimilars.

Biologics can be defined as molecules derived from the living cells such as microorganisms, or plant or animal cells and used in the treatment, diagnosis, or prevention of diseases. Most of the biologic molecules are very large, complex molecules, or mixture of molecules. The U.S. Food and Drug Administration (FDA) defines biosimilar as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

Non-oncology biopharmaceuticals are drugs which are indicated for treatment of a number of diseases except cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Market Dynamics

Frequent launch, approval, and presence of robust pipeline of novel biopharmaceutical products indicated for treatment of number of non-oncology indication is expected to drive the U.S. non-oncology biopharmaceuticals market growth over the forecast period. For instance, in November 2018, Swedish Orphan Biovitrum AB and Novimmune SA received the U.S. Food and Drug Administration (FDA) approval for Gamifant (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (new born and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.

In March 2018, Theratechnologies Inc. and its partner TaiMed Biologics Inc. received the U.S. Food and Drug Administration (FDA) approval for its Trogarzo (ibalizumab-uiyk) Injection. In combination with other ARTs, Trogarzo is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection, who are failing their current antiretroviral regimen.

Key players in the market are adopting inorganic growth strategies such as mergers and partnerships for the development of novel products or to expand their product portfolio by acquisition. Such frequent activities by key players is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in 2016, Teva Pharmaceutical Industries Ltd. and Celltrion Inc. entered into an exclusive partnership to commercialize two of Celltrion's mAb biosimilar candidates in the U.S. and Canada.

In 2016, Shire plc. and Baxalta Incorporated entered into an agreement, under which Shire will combine with Baxalta. Baxalta has a well-established hematology portfolio based on its heritage and legacy of leadership in hemophilia. With this merger, the established company (Shire plc.) will strengthen its position in the market.

Furthermore, high prevalence of various chronic disorders such as diabetes, asthma, cardiovascular diseases, and arthritis in the U.S. is expected to increase demand for biopharmaceutical products and in turn support the non-oncology biopharmaceuticals market growth. For instance, according to the data published by Centers for Disease Control and Prevention (CDC), in 2017, over 100 million U.S. adults were suffering from diabetes or pre-diabetes.

Key features of the study:

  • This report provides in-depth analysis of U.S. non-oncology biopharmaceuticals market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the U.S. Non-oncology biopharmaceuticals market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol - Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The U.S. non-oncology biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the U.S. non-oncology biopharmaceuticals market

Detailed Segmentation:

  • U.S. Non-oncology Biopharmaceuticals Market, By Product Type :
    • Biologics
    • Biosimilars
  • U.S. Non-oncology Biopharmaceuticals Market, By Drug Class:
    • Monoclonal Antibody
    • Enzyme Replacement Therapy
    • Erythropoietin
    • Interferon
    • Colony-stimulating Factor
    • Botulinum Toxin
    • Fusion Protein
    • Vaccines
    • Human Recombinant Insulin
    • Blood Factors
    • Human Growth Hormone
    • Others
  • U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication:
    • Diabetes
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Multiple Sclerosis
    • Hemophilia
    • Anemia
    • Age-related Macular Degeneration
    • Hepatitis B
    • Cystic Fibrosis
    • Osteoporosis
    • Crohn's Disease
    • Ulcerative Colitis
    • Psoriasis
    • Ankylosing Spondylitis
    • Others (Cardiac diseases and others)
  • Company Profiles
    • Sanofi S.A.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Bristol - Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • Novo Nordisk A/S
    • GlaxoSmithKline plc.
    • UCB Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Ltd
    • AstraZeneca Plc
    • Mylan N.V.
    • LEO Pharma A/S
    • Boehringer Ingelheim GmbH
    • Alexion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Elusys Therapeutics, Inc.
    • Swedish Orphan Biovitrum AB
    • Samsung Bioepis NL B.V.
    • Biogen Inc.
    • Theratechnologies Inc.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Indication
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Recent Product Approval/Launch
    • Merger-Acquisition Scenario
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pest Analysis
    • Market Challenges
    • Top 10 Non-oncology Biologics Brand Share
    • Major Biopharmaceuticals Administration Method
    • Analysis Of Mode Of Administration
    • Epidemiology
    • Pest Analysis
    • Porter's Five Forces Analysis

4. U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Biologics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Biosimilars
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

5. U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Blood Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Botulinum Toxin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Colony-stimulating Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Enzyme Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Erythropoietin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Fusion Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Monoclonal Antibody
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Recombinant Human Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

6. U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Age-related Macular Degeneration
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Anemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Ankylosing Spondylitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Crohn's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Hemophilia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Hepatitis B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Multiple Sclerosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Osteoporosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Psoriasis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Psoriatic Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Rheumatoid Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Ulcerative Colitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

7. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bristol - Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • UCB Pharma
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Takeda Pharmaceutical Company Ltd
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • LEO Pharma A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Alexion Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Elusys Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Swedish Orphan Biovitrum AB
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Samsung Bioepis NL B.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Theratechnologies Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact